Trial Profile
CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluorouracil (5-FU) (24 h) in combination with lapatinib as a second-line therapy in pancreatic cancer after gemcitabine failure: A phase I/II trial
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Jun 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CONKO-008
- 15 Jun 2021 This trial has been completed in Germany, according to European Clinical Trials Database.
- 29 Jun 2013 Planned number of patients changed from 18 to 95 as reported by European Clinical Trials Database.
- 29 Jun 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2009-009928-37).